PARP1 and cancer: Lastly, recent data suggested that combined CHK1 and PARP inhibitor treatment is preferentially toxic to KRASmut HTC116 cells23; however, we did not observe any differential cell kill when these inhibitors were combined, possibly highlighting inter-tumoral differences across KRASmut cancers (Suppl.